Incidence and Management of Kaposi Sarcoma in Renal Transplant Recipients: The Greek Experience

Zavos, G.; Moris, Demetrios; Vernadakis, Spiridon; Bokos, John; Lionaki, Sophia; Mamarelis, Georgios; Panagiotellis, Konstantinos; Zavvos, Vasileios; Boletis, Ioannis

doi:10.1016/j.transproceed.2014.09.165

Cited by 23 publications

(18 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Calcineurin inhibitors (CNI) conversion to mTOR inhibitors, such as sirolimus, is usually performed when possible . Indeed, CNI conversion to sirolimus improves pt‐KS prognosis in renal recipients without impairing graft function . In KS samples, vascular endothelial growth factor (VEGF) and mTOR pathways were shown to be upregulated with high expression of VEGF, phospho‐mTOR, and phospho‐P70S6K, supporting the rational for the use of mTOR inhibitor in pt‐KS, In our series, only patient 1 had conversion of tacrolimus to sirolimus because of immunosuppressive management of pt‐KS depended on era and most patients had first transplant before 2000 (Table ).…”

Section: Discussionmentioning

confidence: 62%

Outcome of second kidney transplantation in patients with previous post‐transplantation Kaposi's sarcoma: A French retrospective study

Bohelay

Arzouk

Lévy

et al. 2017

Clinical Transplantation

View full text Add to dashboard Cite

This retrospective study concerned 8 patients with post-transplantation Kaposi's sarcoma (pt-KS) after a first kidney transplant who later had a second kidney transplantation. Pt-KS was widespread, with lymph node or visceral involvement in 7 cases. Complete remission was observed in 6 cases and partial remission in 2. After the second kidney transplantation, only 2 cases showed recurrence of skin KS, one with previous complete remission of KS and one with partial remission. The mean delay between stability or complete remission of KS and retransplantation was 2.0 and 7.3 years in patients with and without relapse, respectively. Both recurrent cases showed complete KS remission after tapering immunosuppression therapy and/or switching a calcineurin inhibitor to a mammalian target of rapamycin inhibitor. We compared these 8 cases to 24 controls who had undergone 2 kidney transplantations but did not have KS, matching on sex, age and phototype. Cases and controls did not differ in graft function or survival. A second kidney transplantation may be possible after pt-KS and has acceptable risk, especially after a long complete remission of pt-KS.

show abstract

Section: Discussionmentioning

confidence: 62%

Outcome of second kidney transplantation in patients with previous post‐transplantation Kaposi's sarcoma: A French retrospective study

Bohelay

Arzouk

Lévy

et al. 2017

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…Soft tissue sarcomas are rare tumors of mesenchymal origin (10). In transplant patients, with the exception of Kaposi sarcoma-which is relatively common with a 400-500-fold increased incidence-soft tissue sarcomas are rarely encountered, thus the diagnostic and treatment algorithms follow those of general population (11)(12)(13).…”

Section: Discussionmentioning

confidence: 99%

Primary thoracic chondrosarcoma with intra‑abdominal extension in a renal transplant recipient: A case report

et al. 2020

View full text Add to dashboard Cite

Primary thoracic bone tumors are relatively rare. The most common type is chondrosarcoma, accounting for up to 48% of all cases. Patients with primary thoracic bone tumors commonly present with atypical thoracic pain or a solitary palpable chest mass, which gradually develops over months to years. The bones most often affected are the ribs, scapula, costochondral junctions and the sternum. The present study presents a case of a 79 year old previous transplant recipient with a large intra-abdominally expanding chondrosarcoma originating from the left lower thoracic cage and associated vague abdomdinal symptoms. Early recognition and awareness of atypical presentations of this disease are important in to appropriately guide diagnostic evaluation and therapeutic procedures.

show abstract

“…El SK iatrogénico ha sido reportado en pacientes con inmunosupresión farmacológica, tanto en aquellos con enfermedades sistémicas como en pacientes trasplantados. La frecuencia del SK en pacientes trasplantados oscila entre 1,2 y 8%, mientras que en pacientes con inmunosupresión farmacológica por otras causas, su incidencia sería 2-4 veces menor 15,25,26 . Aunque puede tener un curso agresivo y compromiso visceral frecuente, ninguno de los pacientes incluidos en este estudio presentó esta evolución.…”

Section: Discussionunclassified

Sarcoma de Kaposi: variedades clínicas y resultados del tratamiento local con radioterapia

Vargas

2018

Rev. méd. Chile

View full text Add to dashboard Cite

show abstract

Incidence and Management of Kaposi Sarcoma in Renal Transplant Recipients: The Greek Experience

Cited by 23 publications

References 10 publications

Outcome of second kidney transplantation in patients with previous post‐transplantation Kaposi's sarcoma: A French retrospective study

Outcome of second kidney transplantation in patients with previous post‐transplantation Kaposi's sarcoma: A French retrospective study

Primary thoracic chondrosarcoma with intra‑abdominal extension in a renal transplant recipient: A case report

Sarcoma de Kaposi: variedades clínicas y resultados del tratamiento local con radioterapia

Contact Info

Product

Resources

About